Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Sebelipase Alfa in LAL Deficiency
NCT01488097Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Dec 2011
- Primary completion
- Jun 2017
- Modality
- Replacement Enzymes
- Countries
- 5
01
Overview
A Phase 2 trial of sebelipase alfa in lysosomal acid lipase deficiency (LALD), sponsored by Alexion Pharmaceuticals. Started Dec 2011; status: completed.
02
Drugs
sebelipase alfa
03
Conditions
lysosomal acid lipase deficiency (LALD)
Beyond the preview
Go deeper on NCT01488097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488097.